NCT06781632View on ClinicalTrials.gov

Phase I Study of Ropivacaine, Clonidine, and Betamethasone Combination for Sciatic Nerve Block in the Popliteal Region

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 13, 2024

Primary Completion Date

February 20, 2025

Study Completion Date

April 25, 2025

Conditions
HealthyNerve Block
Interventions
DRUG

ropivacaine

Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)

Trial Locations (1)

34093

Istanbul University, Istanbul Faculty of Medicine Phase I and Clinical Research Center, Istanbul

Sponsors

Lead Sponsor

PHARMAFINA
All Listed Sponsors
collaborator

MonitorCRO

INDUSTRY

lead

PHARMAFINA

INDUSTRY

NCT06781632 - Phase I Study of Ropivacaine, Clonidine, and Betamethasone Combination for Sciatic Nerve Block in the Popliteal Region | Biotech Hunter | Biotech Hunter